All News

2058 articles, sorted by publication time.

Clinical Trials · global

Breaching Cancer Cells’ Defenses Through Telomere Damage: MAIA Doses First U.S. Patient in Phase 2 Lung Cancer Trial

Ateganosine aims to damage cancer cell telomeres before subsequent immunotherapy, seeking a path forward for lung cancer patients whose existing treatments have failed. Dosing the first U.S. patient marks another step for the research, but whether this strategy can deliver durable efficacy remains a question for clinical data.

New Cancer Drugs · global

Full SAFFRON data released: Dual targeted therapy extends median survival by 4.9 months over chemotherapy in a specific drug-resistant lung cancer population

Following the announcement that the trial met its endpoint, the disclosure of the magnitude of benefit adds survival evidence for savolitinib plus osimertinib in drug-resistant lung cancer with high MET expression or amplification. However, the dual oral regimen still carries a substantial treatment burden, with a rate of grade 3 or higher adverse events similar to chemotherapy.